Abstract
The developing brain is particularly vulnerable to internal and external stressors, and it is no surprise that clinicians in the field of neonatal neurology fiercely debate the urgency of treating neonatal seizures while at the same token advocate minimizing exposure to potentially toxic antiseizure medications (ASMs). In this issue of Neurology® Clinical Practice , Carrasco et al.1 explored the evidence for early discontinuation of ASMs after acute symptomatic seizures in neonates and provide a pragmatic framework for clinicians to use in practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
